东阳光药涨近7% 中期毛利14.68亿元 伊非尼酮关键数据亮相美国IPF峰会

Group 1 - Dongyangguang Pharmaceutical (东阳光药) shares increased nearly 7%, reaching HKD 53.95 with a trading volume of HKD 20.61 million [1] - The company reported a mid-year revenue of RMB 1.938 billion and a gross profit of RMB 1.468 billion for 2025 [1] - The sales of the company's oseltamivir product were affected by a slowdown in flu cases compared to the previous year, generating revenue of RMB 1.301 billion while maintaining industry leadership [1] Group 2 - The company showcased its innovative anti-fibrotic drug, HEC585, at the 9th Idiopathic Pulmonary Fibrosis (IPF) Summit held in Boston from August 19 to 21, 2025 [1] - HEC585 is the first domestically developed IPF drug to enter Phase III clinical trials and has potential applications for progressive fibrosing interstitial lung disease (PF-ILD), hepatitis B liver fibrosis, and interstitial pneumonia [2] - The drug works by simultaneously inhibiting the release of TNF-α and TGF-β1, blocking the TGF-β1-Smad signaling pathway, and regulating various signaling pathways to form a comprehensive anti-fibrotic network [2]